ANG Lifesciences India Ltd
ANGANG Lifesciences India Ltd
ANG
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -4.08 | 0.79 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 50.26 | 6.38 | 0.53% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
ANG Lifesciences India is a pharmaceutical company, engaged in the business of manufacturing and marketing of finished pharmaceutical formulations in a dosage form of sterile dry powder injection vials
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 154.93 | 355.20 | 229.61 | 146.81 | 109.47 | |||||
Raw Materials | 140.12 | 234.65 | 156.08 | 102.79 | 107.40 | |||||
| Power & Fuel Cost | 6.14 | 6.50 | 4.15 | |||||||
| Employee Cost | 21.29 | 23.97 | 19.35 | |||||||
| Selling & Administrative Expenses | 18.70 | 15.49 | 12.85 | |||||||
| Operating & Other expenses | 5.62 | 3.12 | -1.39 | |||||||
EBITDA | 14.81 | 68.80 | 24.45 | 9.06 | 2.07 | |||||
| Depreciation/Amortization | 1.33 | 5.88 | 9.35 | 8.37 | 7.33 | |||||
| PBIT | 13.48 | 62.92 | 15.10 | 0.69 | -5.26 | |||||
| Interest & Other Items | 3.52 | 9.42 | 12.48 | 11.41 | 10.61 | |||||
| PBT | 9.96 | 53.50 | 2.62 | -10.72 | -15.87 | |||||
| Taxes & Other Items | 3.11 | 13.19 | 2.89 | -0.57 | -1.14 | |||||
| Net Income | 6.85 | 40.31 | -0.27 | -10.15 | -14.73 | |||||
| EPS | 4.74 | 31.11 | -0.21 | -7.77 | -11.28 | |||||
| DPS | — | 0.80 | 0.00 | 0.00 | 0.00 | |||||
| Payout ratio | 0.00 | 0.03 | 0.00 | 0.00 | 0.00 |
Company Updates
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| ANG Lifesciences India Ltd | -5.92 | 0.79 | — |
| Sun Pharmaceutical Industries Ltd | 44.98 | 6.42 | 0.75% |
| Cipla Ltd | 29.13 | 4.48 | 0.87% |
| Torrent Pharmaceuticals Ltd | 64.71 | 15.63 | 0.88% |
Price Comparison
Compare ANG with any stock or ETFShareholdings
Promoter Holdings Trend
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateNov 2, 2021
Dividend/Share
₹1.00
Ex DateEx Date
Nov 2, 2021
Net Loss of ANG Lifesciences India reported to Rs 2.09 crore in the quarter ended September 2024 as against net loss of Rs 2.32 crore during the previous quarter ended September 2023. Sales declined 1.14% to Rs 32.88 crore in the quarter ended September 2024 as against Rs 33.26 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales32.8833.26 -1 OPM %6.964.99 - PBDT0.45-0.41 LP PBT-1.29-2.63 51 NP-2.09-2.32 10 Powered by Capital Market - Live
ANG Lifesciences India will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live
ANG Lifesciences India announced that the Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live
ANG Lifesciences India announced that the Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live
Net loss of ANG Lifesciences India reported to Rs 3.07 crore in the quarter ended June 2024 as against net profit of Rs 1.75 crore during the previous quarter ended June 2023. Sales declined 67.39% to Rs 18.41 crore in the quarter ended June 2024 as against Rs 56.46 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales18.4156.46 -67 OPM %-9.2311.58 - PBDT-2.514.55 PL PBT-4.142.36 PL NP-3.071.75 PL Powered by Capital Market - Live
ANG Lifesciences India will hold a meeting of the Board of Directors of the Company on 14 August 2024.Powered by Capital Market - Live
North Eastern Carrying Corporation Ltd leads losers in ‘B’ group
Alps Industries Ltd leads losers in ‘B’ group
ANG Lifesciences India Ltd leads losers in ‘B’ group
Multibagger pharma stock announces record date for bonus issue
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
High Pledged Promoter Holding
A significant proportion of promoter holdings is pledged